BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Hidradenitis suppurativa clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for hidradenitis suppurativa: 60 (30 sponsors; 12 newly posted in the last 180 days, 2 stopped in the last 180 days; 6 new-entrant sponsors). Momentum score 22.5, rank 19 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 7, Phase 2 22, Phase 3 13, Phase 4 1, N/A 17.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Incyte Corporation INCY6P3 4, P1 1, P2 102
Novartis Pharmaceuticals NVS14NA 9, P3 3, P4 1, P1 134
AbbVie ABBV5NA 1, P2 2, P3 202
Institut Pasteur2NA 1, P3 101
UCB Biopharma SRL2P1 1, P3 101
Bluefin Biomedicine, Inc.1P3 100
MoonLake Immunotherapeutics AG MLTX1P3 100
Sanofi SNY4P1 1, P2 321
Almirall, S.A.2P2 201
Sonoma Biotherapeutics, Inc. SNOA2P1 1, NA 100
Target PharmaSolutions, Inc. TGT2NA 210
Aroa Biosurgery Limited1NA 100
Citryll BV1P2 101
Corvus Pharmaceuticals, Inc. CRVS new entrant1P1 110
Integra LifeSciences Corporation IART new entrant1NA 110
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.1P2 100
Merck Sharp & Dohme LLC MRK1P2 100
Navigator Medicines, Inc. NVGS1P2 100
Oruka Therapeutics, Inc. ORKA new entrant1P2 110
Pfizer PFE1P2 101
Power Life Sciences Inc.1NA 100
Qilu Pharmaceutical Co., Ltd.1P2 100
Regeneron Pharmaceuticals REGN new entrant1P2 110
Shanghai Huaota Biopharmaceutical Co., Ltd.1P2 100
Shanghai Qilu Pharmaceutical Research and Development Center LTD1P1 100

New-entrant sponsors: Corvus Pharmaceuticals, Inc., Integra LifeSciences Corporation, Oruka Therapeutics, Inc., Regeneron Pharmaceuticals.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P3AbbVie ABBVNCT06468228 A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativaactive not recruiting1400
2026-12-08 est.P2Pfizer PFENCT07228390 A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, HidradenitiHidradenitis Suppurativaactive not recruiting128
2026-12-21 est.P3UCB Biopharma SRLNCT06921850 A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativaactive not recruiting43
2026-12-26 est.P3Incyte Corporation INCYNCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativa (HS)active not recruiting617
2027-02 est.P2AbbVie ABBVNCT06524635 A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis ReceivinHidradenitis Suppurativa; Atopic Dermatitisrecruiting60
2027-02 est.P2Almirall, S.A.NCT07547813 A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis SuppurativaHidradenitis Suppurativarecruiting50
2027-02-05 est.P2Takeda TAKNCT07244263 A Study of Zasocitinib in Adults With Hidradenitis SuppurativaHidradenitis Suppurativaactive not recruiting91
2027-02-09 est.P2Sanofi SNYNCT07170917 Brivekimig for the Treatment of Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativarecruiting208

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-29P3Incyte Corporation INCYNCT06959225 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Hidradenitis Suppurativaactive not recruiting580
2026-10-01P3Incyte Corporation INCYNCT06958211 Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Hidradenitis Suppurativaactive not recruiting573
2026-09-28P3MoonLake Immunotherapeutics AG MLTXNCT06768671 An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis SuppuratHidradenitis Suppurativacompleted35
2026-09-18P2Zura Bio Inc ZURANCT06993610 Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseHidradenitis Suppurativa (HS)active not recruiting247
2026-07-22P3UCB Biopharma SRLNCT04901195 A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaHidradenitis Suppurativacompleted658

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hidradenitis suppurativa"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.